Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Rubius Therapeutics, a clinical-stage biopharmaceutical company, announces that Dr. Pablo J. Cagnoni, CEO, will present at the virtual 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rubius Therapeutics, a clinical-stage biopharmaceutical company, announces that Dr. Pablo J. Cagnoni, CEO, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 8:15 a.m. ET. The presentation will focus on the company's innovative Red Cell Therapeutics™ aimed at treating cancer and autoimmune diseases. A live audio webcast will be accessible through the Investors & Media section of their website, with a replay available for 30 days post-event. Rubius has been recognized as a top workplace in Massachusetts and Rhode Island.
Details
News Market Reaction – RUBY
The recorded move for RUBY in the trading session of this news was -4.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:15 a.m. ET.
A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 30 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to biologically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Investors
Elhan Webb, CFA, VP Investor Relations
elhan.webb@rubiustx.com
Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.